参考文献/References:
[1] Stanbury JB,Ermans AE,Bourdoux P,et al.Iodine-induced hyperthyroidism:occurrence and epidemiology[J].Thyroid,1998,8(1):83-100.DOI:10.1089/thy.1998.8.83.
[2] Petersen M,Knudsen N,Carlé A,et al.Thyrotoxicosis after iodine fortification.A 21-year Danish population-based study[J].Clin Endocrinol(Oxf),2018,89(3):360-366.DOI:10.1111/cen.13751.
[3] Riis J,Andersen SL,Gade GV,et al.Raised mortality in old adults with a history of hyperthyroidism following iodine fortification[J].Clin Endocrinol(Oxf),2022,96(2):255-262.DOI:10.1111/cen.14627.
[4] Yang F,Teng W,Shan Z,et al.Epidemiological survey on the relationship between different iodine intakes and the prevalence of hyperthyroidism[J].Eur J Endocrinol,2002,146(5):613-618.DOI:10.1530/eje.0.1460613.
[5] Yang F,Shan Z,Teng X,et al.Chronic iodine excess does not increase the incidence of hyperthyroidism:a prospective community-based epidemiological survey in China[J].Eur J Endocrinol,2007,156(4):403-408.DOI:10.1530/EJE-06-0651.
[6] Shan Z,Chen L,Lian X,et al.Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China:a cross-sectional study in 10 cities[J].Thyroid,2016,26(8):1125-1130.DOI:10.1089/thy.2015.0613.
[7] Li Y,Teng D,Ba J,et al.Efficacy and safety of long-term universal salt iodization on thyroid disorders:epidemiological evidence from 31 provinces of mainland China[J].Thyroid,2020,30(4):568-579.DOI:10.1089/thy.2019.0067.
[8] Ali SA,Ersbøll M,Vinding NE,et al.Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure:a nationwide cohort study[J].Europace,2023,25(2):291-299.DOI:10.1093/europace/euac217.
[9] Bartalena L,Bogazzi F,Chiovato L,et al.2018 European Thyroid Association(ETA)Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction[J].Eur Thyroid J,2018,7(2):55-66.DOI:10.1159/000486957.
[10] 中华医学会内分泌学分会,中国医师协会内分泌代谢科医师分会,中华医学会核医学分会,等.中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J].中华内分泌代谢杂志,2022,38(8):700-748.DOI:10.3760/cma.j.cn311282-20220624-00404.
[11] Perrone MA,Babu Dasari J,Intorcia A,et al.Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism:a clinical study[J].Eur Rev Med Pharmacol Sci,2018,22(23):8502-8508.DOI:10.26355/eurrev_201812_16551.
[12] Inoue K,Guo R,Lee ML,et al.Iodinated contrast administration and risks of thyroid dysfunction:a retrospective cohort analysis of the U.S.veterans health administration system[J].Thyroid,2023,33(2):230-238.DOI:10.1089/thy.2022.0393.
[13] Bervini S,Trelle S,Kopp P,et al.Prevalence of iodine-induced hyperthyroidism after administration of iodinated contrast during radiographic procedures:a systematic review and meta-analysis of the literature[J].Thyroid,2021,31(7):1020-1029.DOI:10.1089/thy.2020.0459.
[14] Bednarczuk T,Brix TH,Schima W,et al.2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction[J].Eur Thyroid J,2021,10(4):269-284.DOI:10.1159/000517175.
[15] Huang H,Shi Y,Liang B,et al.Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction[J].Clin Endocrinol(Oxf),2018,88(3):473-478.DOI:10.1111/cen.13543.
[16] Hiraiwa T,Ito M,Imagawa A,et al.Restriction of dietary Iodine does not ameliorate the early effect of anti-thyroid drug therapy for Graves' disease in an area of excessive iodine intake[J].J Endocrinol Invest,2006,29(4):380-384.DOI:10.1007/BF03344113.
[17] Okamura K,Sato K,Fujikawa M,et al.Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects[J].J Clin Endocrinol Metab,2014,99(11):3995-4002.DOI:10.1210/jc.2013-4466.
[18] Sato S,Noh JY,Sato S,et al.Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism[J].Thyroid,2015,25(1):43-50.DOI:10.1089/thy.2014.0084.
[19] Okamura K,Sato K,Fujikawa M,et al.Iodide-sensitive Graves' hyperthyroidism and the strategy for resistant or escaped patients during potassium iodide treatment[J].Endocr J,2022,69(8):983-997.DOI:10.1507/endocrj.EJ21-0436.
[20] Kamijo K.Clinical studies on potassium iodide-induced painless thyroiditis in 11 Graves' disease patients[J].Intern Med,2021,60(11):1675-1680.DOI:10.2169/internalmedicine.6411-20.
相似文献/References:
[1]曹雯,郑仁东,陈国芳,等.甲状腺功能亢进症伴严重药物性胆汁郁积性肝炎1例并文献复习[J].国际内分泌代谢杂志,2014,(03):214.[doi:10.3760/cma.j.issn.1673-4157.2014.03.020]
Cao Wen,Zheng Rendong,Chen Guofang,et al.One case of hyperthyroidism with severe drug-induced cholestasis hepatitis and literature review[J].International Journal of Endocrinology and Metabolism,2014,(04):214.[doi:10.3760/cma.j.issn.1673-4157.2014.03.020]
[2]陈堃,陈国芳,郑仁东,等.碳酸锂对甲状腺功能和形态的影响[J].国际内分泌代谢杂志,2014,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2014.04.009]
Chen Kun,Chen Guofang,Zheng Rendong,et al.Effects of carbonate lithium therapy on morphology and function of thyroid gland[J].International Journal of Endocrinology and Metabolism,2014,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2014.04.009]
[3]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
[4].中国甲状腺功能亢进症和其他原因
所致甲状腺毒症诊治指南[J].国际内分泌代谢杂志,2022,42(05):401.[doi:10.3760/cma.j.cn311282-20220624-00404]